CClinicalTrials.gg
CompletedNCT04001348Updated Jun 28, 2019

Characteristics of Different Types of Safety Lancets on Blood Volume and Perceived Pain in Male and Female Volunteers

An interventional study of Acti-Lance Lite and Acti-Lance Universal in Healthy, sponsored by HTL-Strefa S.A.. Completed at 1 site in Poland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-28.

Sponsored by HTL-Strefa S.A. · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study was a randomized, single blind, uni-center pivotal study in male and female healthy volunteers, to determine capillary blood volume and pain perception obtained in a process of puncturing with different safety lancets.

A group of one hundred (100) healthy Caucasian male and female Subjects (aged > 18 to \< 65 years old was randomized ) who were in good physical and mental condition. The Subjects had 4 (four) fingers (two fingers from each hand) lanced each with a different type of safety lancet. Overall, 4 (four) different safety lancets were investigated per each Subject.

Overall, 16 (sixteen) different safety lancets (4 different safety lancets per one Subject) were investigated, the capillary blood volume and pain were measured.

02

Conditions studied

  • Healthy

Keywords

  • safety lancets
  • lancet
  • capillary blood
  • capillary blood sampling
  • blood volume
  • pain
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Willing to sign the informed consent.
  • Male and female volunteers.
  • Age between 18 and 65 inclusive.
  • Able to communicate well with the Investigator and comply with the requirements of the study.
  • Volunteers who are in good physical and mental health.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding (self-reported).
  • Confirmed or suspected malignant cancer History of poor blood circulation.
  • Any skin condition on his or her fingers that prevents blood sampling.
  • Anxiety with needles or finger pricks.
  • Clotting disorders (including bleeding) in medical history.
  • Neuropathy or other condition affecting sensation in the hands.
  • History of blood borne infection (e.g., HIV, hepatitis B or C, syphilis, malaria, babesiosis, brucellosis, leptospirosis, arboviral infections, relapsing fever, T lymphotropic virus Type 1, Creutzfeldt-Jakob disease).
  • Currently participating in another study.
  • History of drug or alcohol abuse within the 12 months prior to screening or evidence of such abuse.
  • Intake of alcohol within 48 hours prior to the start of the study (self-reporting).
  • Donation or loss of 400 mL or more of blood within 4 weeks prior to the start of the study.
  • Any other condition that in the Investigator opinion may negatively influence Subject's participation in the study.
  • Intake of medicines that affect blood coagulability (including anticoagulants such as vitamin K, antivirals and anticoagulants such as heparin, aspirin, thrombin inhibitors, vitamin K antagonists).
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    HTL-STREFA S.A.safety lancet type 610

    Device: Acti-Lance Lite · Device: Acti-Lance Universal · Device: Acti-Lance Special

  • Experimental
    HTL-STREFA S.A.safety lancet type 553-556

    Device: Medlance Plus Super Lite · Device: Medlance Plus Lite · Device: Medlance Plus Universal · Device: Medlance Plus Extra · Device: Medlance Plus Special

  • Experimental
    HTL-STREFA S.A.safety lancet type 430

    Device: Prolance Micro Flow · Device: Prolance Low Flow · Device: Prolance Normal Flow · Device: Prolance High Flow · Device: Prolance Max Flow · Device: Prolance Pediatric

  • Experimental
    HTL-STREFA S.A.safety lancet type 520

    Device: MediSafe Solo 29 Gauge · Device: MediSafe Solo 23 Gauge

Interventions

  • DeviceActi-Lance Lite

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 610

  • DeviceActi-Lance Universal

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 610

  • DeviceActi-Lance Special

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 610

  • DeviceMedlance Plus Super Lite

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 553-556

  • DeviceMedlance Plus Lite

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 553-556

  • DeviceMedlance Plus Universal

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 553-556

  • DeviceMedlance Plus Extra

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 553-556

  • DeviceMedlance Plus Special

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 553-556

  • DeviceProlance Micro Flow

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 430

  • DeviceProlance Low Flow

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 430

  • DeviceProlance Normal Flow

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 430

  • DeviceProlance High Flow

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 430

  • DeviceProlance Max Flow

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 430

  • DeviceProlance Pediatric

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 430

  • DeviceMediSafe Solo 29 Gauge

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 520

  • DeviceMediSafe Solo 23 Gauge

    Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol. Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure.

    Also known as: HTL-STREFA S.A.safety lancet type 520

05

What researchers measure

Primary outcomes

  1. Volume (microliters) of blood in the capillary tube

    The amount of capillary blood volume collected after a single lancing of the fingertip.

    Time frame: The blood from the puncture site was collected to the capillaries by pressing during 2 minutes

Secondary outcomes

  1. Pain perception: VAS

    The intensity of pain perceived by the patient was assessed with the use of the numeric Visual Analog Scale (VAS). The Subject marked on the scale the number from 0 ("no pain") to 10 ("worst imaginable pain") that represented their perception of pain. A higher score indicated greater pain intensity.

    Time frame: 5 minutes after lancing

06

Study locations

1 site
  • Monipol Clinical Pharmacology Research Centre
    Cracovia, Malopolskie 30-969, Poland
07

References and documents

Publications

  • Serafin A, Malinowski M, Prazmowska-Wilanowska A. Blood volume and pain perception during finger prick capillary blood sampling: are all safety lancets equal? Postgrad Med. 2020 Apr;132(3):288-295. doi: 10.1080/00325481.2020.1717160. Epub 2020 Feb 6. PubMed 32027205 ↗
08

Registry details

Key details

Study ID
NCT04001348
Lead sponsor
HTL-Strefa S.A.
Responsible party
Sponsor
First posted
Jun 28, 2019
Start date
Jun 2013
Primary completion
Jul 2013
Completion
Jul 2013
Last update
Jun 28, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion